## **Core Concept**
The core concept here revolves around the management and prevention of **Genital Herpes** infection during pregnancy, particularly in a woman with a history of recurrent infections. The goal is to minimize the risk of **neonatal herpes**, a potentially severe condition.

## **Why the Correct Answer is Right**
The correct approach involves understanding that women with a history of recurrent genital herpes can usually be managed conservatively. The risk of **neonatal herpes** is higher with primary infections than with recurrent infections. For women with recurrent genital herpes, the risk of neonatal herpes is low, approximately **1-3%**. The management typically involves **suppressive therapy** with antiviral medications like **acyclovir** or **valacyclovir** from **36 weeks of gestation** onwards to reduce the risk of an outbreak and, consequently, the risk of neonatal herpes.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is not provided, but typically, incorrect options might suggest immediate antiviral therapy regardless of gestational age or not addressing the concern for neonatal exposure.
- **Option B:** Similarly, not provided, but could involve incorrect management strategies such as immediate cesarean section or not considering the timing of suppressive therapy.
- **Option D:** Without specifics, one might assume this involves an overly aggressive approach or one that doesn't consider current guidelines for managing recurrent genital herpes in pregnancy.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that for women with recurrent genital herpes, **suppressive antiviral therapy** starting at **36 weeks of gestation** is recommended to decrease the risk of **neonatal herpes**. This approach helps in reducing viral shedding and the risk of an outbreak around the time of delivery.

## **Correct Answer:** C. Offer suppressive antiviral therapy from 36 weeks of gestation.